Esperion Stock Soars 18.99% on Institutional Buying

On May 27, 2025, Esperion's stock surged by 18.99% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Esperion Therapeutics has seen notable changes in institutional holdings, with D. E. Shaw & Co. Inc. increasing its stake by 152.7% during the fourth quarter. Other major investors, including Wasatch Advisors LP, Bank of America Corp DE, JPMorgan Chase & Co., Connor Clark & Lunn Investment Management Ltd., and Sigma Planning Corp, have also adjusted their positions in the company, reflecting a growing interest in Esperion's potential.

Recent earnings reports from Esperion Therapeutics showed a loss of $0.21 per share for the quarter, slightly missing analyst estimates. Despite this, the company's revenue of $65.00 million exceeded expectations, indicating strong performance in certain areas. Analysts have provided mixed ratings for the stock, with some maintaining a "buy" rating while others have downgraded their price targets. The consensus rating remains a "Hold," with a price target of $6.25.

Esperion Therapeutics focuses on developing and commercializing medicines for the treatment of elevated LDL cholesterol. Its flagship products, NEXLETOL and NEXLIZET, are oral, once-daily, non-statin medicines designed to lower LDL-C levels in patients with primary hyperlipidemia and atherosclerotic cardiovascular disease. The company's innovative approach to cholesterol management has positioned it as a key player in the biopharmaceutical industry.